SITE HEAD
Kaitong Li
Facility Management

BEIJING, CHINA

Key Features

Our partner, JOINN Labs, supports clinical bioanalytical studies in Beijing, located in the hub of the Chinese biopharmaceutical sector. The location is a 1,500-employee, FDA-audited, pioneering GLP service provider in China.

- Support for global clinical trials
- Record of drug development
  - Over 1,400 compounds evaluated
  - Over 130 applications submitted to the U.S. FDA
- Over 600 scientific staff with diversified expertise
  - Diabetes
  - Cancer
  - Immunoregulation disorders
  - Vaccines

Key Abilities

- Clinical grade testing
- Drug evaluations of biologics, pharmaceutical chemicals, and botanicals for a diverse set of indications

Laboratory

- 13,000 square meter (140,000 square foot) facility
- 8,100 square meter (87,000 square foot) area dedicated to animal facilities
  - Conventional animal holding
  - Specific pathogen-free (SPF)
  - BSL-2

Notable Certifications: AAALAC Accredited, U.S. FDA GLP Inspected*, CFDA GLP Certified, OECD GLP Certified, Korean MFDS GLP Inspected

*First Chinese CRO to be inspected by the U.S. FDA for GLP compliance and to be certified by CFDA

EQUIPMENT AND TECHNIQUES

Testing Capabilities

- ELISA
- Neutralization assays
- qPCR using fully validated assays (after technology transfers from Nexelis)

Equipment

- BECKMAN Vi-CELL XR
- Roche Cobas e411
- CTL S6 UNIVERSAL
- Beckman Coulter Biotechnology DxFLEX
- Luminex TM200
- MSD QuickPlex SQ 120
- INTREGRAT
- MolecularDevices, LLC. SpectraMax® i3x
- Molecular Devices, LLC. SpectraMax® Plus 384
- Applied Biosystems Quant Studio5

ABOUT NEXELIS

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic, and oncologic fields. Our versatile team of scientists, working with state-of-the-art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, and gene and cell therapy products.

BEIJING, CHINA
No.5 Rongjingdong St.
Beijing Economic and Development Area
Beijing China, 100176

LAVAL, CANADA, QC
GOSSELIES, BELGIUM
INDIANAPOLIS, IN, USA
MARBURG, GERMANY
PORTON DOWN, UK
SEATTLE, WA, USA

Nexelis.com